mefenamic acid has been researched along with niflumic acid in 21 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (4.76) | 18.7374 |
| 1990's | 8 (38.10) | 18.2507 |
| 2000's | 5 (23.81) | 29.6817 |
| 2010's | 7 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, TK; Ensom, MH; Kiang, TK | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Fujiwara, R; Koga, T; Nakajima, M; Yokoi, T | 1 |
| Bartlett, SJ; Bauche, A; Fliegert, R; Guse, AH; Harneit, A; Kirchberger, T; Moreau, C; Potter, BV; Swarbrick, JM; Yorgan, T | 1 |
| Bennis, K; Ducki, S; Lesage, F; Vivier, D | 1 |
| Brodsky, JL; Chiang, A; Chung, WJ; Denny, RA; Goeckeler-Fried, JL; Havasi, V; Hong, JS; Keeton, AB; Mazur, M; Piazza, GA; Plyler, ZE; Rasmussen, L; Rowe, SM; Sorscher, EJ; Weissman, AM; White, EL | 1 |
| Leynadier, F; Perrault, M | 1 |
| Cook, DI; Poronnik, P; Ward, MC | 1 |
| Dahlem, D; Englert, HC; Gögelein, H; Lang, HJ | 1 |
| Bertrand, PP; Galligan, JJ | 1 |
| Ottolia, M; Toro, L | 1 |
| Busch, AE; Herzer, T; Lang, F; Raber, G; Schmidt, F; Wagner, CA; Waldegger, S | 1 |
| Bracht, A; Ishii-Iwamoto, EL; Kelmer-Bracht, AM | 1 |
| Greenwood, IA; Large, WA | 1 |
| Bracht, A; Ishii-Iwamoto, EL; Kelmer-Bracht, AM; Lopez, CH; Sampaio, E; Yamamoto, NS | 1 |
| Polásek, M; Pospísilová, M; Urbánek, M | 1 |
| Katz, U; Nagel, W; Somieski, P | 1 |
| Gaganis, P; Knights, KM; Miners, JO | 1 |
| Habjan, S; Vandenberg, RJ | 1 |
| Domańska, U; Pelczarska, A; Pobudkowska, A | 1 |
| Hatzidimitriou, AG; Kefala, LA; Kessissoglou, DP; Papadopoulos, AN; Perdih, F; Psomas, G; Tsiliou, S; Turel, I | 1 |
2 review(s) available for mefenamic acid and niflumic acid
| Article | Year |
|---|---|
UDP-glucuronosyltransferases and clinical drug-drug interactions.
Topics: Clinical Trials as Topic; Drug Interactions; Enzyme Activation; Enzyme Induction; Glucuronides; Glucuronosyltransferase; Humans; Pharmaceutical Preparations; Pharmacogenetics; Polymorphism, Genetic | 2005 |
Perspectives on the Two-Pore Domain Potassium Channel TREK-1 (TWIK-Related K(+) Channel 1). A Novel Therapeutic Target?
Topics: Arrhythmias, Cardiac; Depression; Epilepsy; Humans; Inflammation; Models, Molecular; Molecular Structure; Neuroprotective Agents; Pain; Potassium Channels, Tandem Pore Domain; Structure-Activity Relationship | 2016 |
19 other study(ies) available for mefenamic acid and niflumic acid
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Toxicological evaluation of acyl glucuronides of nonsteroidal anti-inflammatory drugs using human embryonic kidney 293 cells stably expressing human UDP-glucuronosyltransferase and human hepatocytes.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Camphanes; Comet Assay; DNA Damage; Glucuronides; Glucuronosyltransferase; HEK293 Cells; Hepatocytes; Humans; Kidney | 2011 |
Structure-activity relationship of adenosine 5'-diphosphoribose at the transient receptor potential melastatin 2 (TRPM2) channel: rational design of antagonists.
Topics: Adenosine Diphosphate Ribose; Dose-Response Relationship, Drug; Drug Design; Humans; Models, Molecular; Molecular Structure; Structure-Activity Relationship; TRPM Cation Channels | 2013 |
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
Topics: Alleles; Benzoates; Cells, Cultured; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Endoplasmic Reticulum; Furans; Gene Deletion; HEK293 Cells; HeLa Cells; High-Throughput Screening Assays; Humans; Hydroxamic Acids; Microscopy, Fluorescence; Protein Folding; Protein Structure, Tertiary; Pyrazoles; RNA, Messenger; Small Molecule Libraries; Ubiquitination; Vorinostat | 2016 |
[Anti-inflammatory agents in current therapeutics].
Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Aspirin; Asthma; Bursitis; Colchicine; Collagen Diseases; Dexamethasone; Drug Hypersensitivity; Drug Interactions; Flufenamic Acid; Gastrointestinal Hemorrhage; Hallucinations; Humans; Mefenamic Acid; Niflumic Acid; Phenylbutazone; Spondylitis, Ankylosing; Tendinopathy; Triamcinolone; Vertigo | 1975 |
Intracellular Ca2+ release by flufenamic acid and other blockers of the non-selective cation channel.
Topics: Animals; Animals, Newborn; Calcium; Cell Line; Flufenamic Acid; Ion Channels; Mefenamic Acid; Mice; Molecular Structure; Niflumic Acid | 1992 |
Flufenamic acid, mefenamic acid and niflumic acid inhibit single nonselective cation channels in the rat exocrine pancreas.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cations; Electric Conductivity; Flufenamic Acid; In Vitro Techniques; Ion Channels; Mefenamic Acid; Nicotinic Acids; Niflumic Acid; Pancreas; Rats | 1990 |
Contribution of chloride conductance increase to slow EPSC and tachykinin current in guinea-pig myenteric neurones.
Topics: Animals; Chloride Channels; Colforsin; Guinea Pigs; Male; Mefenamic Acid; Myenteric Plexus; Neural Conduction; Niflumic Acid; Peptide Fragments; Substance P; Synaptic Transmission; Tachykinins | 1994 |
Potentiation of large conductance KCa channels by niflumic, flufenamic, and mefenamic acids.
Topics: Animals; Biophysical Phenomena; Biophysics; Calcium; Charybdotoxin; Electrochemistry; Flufenamic Acid; In Vitro Techniques; Kinetics; Mefenamic Acid; Niflumic Acid; Potassium Channels; Scorpion Venoms; Tetraethylammonium; Tetraethylammonium Compounds | 1994 |
Positive regulation by chloride channel blockers of IsK channels expressed in Xenopus oocytes.
Topics: 4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid; Animals; Calcium; Chloride Channels; Flufenamic Acid; Humans; Mefenamic Acid; Membrane Potentials; Niflumic Acid; Oocytes; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Recombinant Proteins; RNA, Complementary; Xenopus | 1994 |
Transport, distribution space and intracellular concentration of the anti-inflammatory drug niflumic acid in the perfused rat liver.
Topics: Animals; Biological Transport; Biotransformation; Extracellular Space; Liver; Male; Mathematics; Mefenamic Acid; Niflumic Acid; Perfusion; Portal Vein; Radioisotope Dilution Technique; Rats; Serum Albumin; Tritium | 1993 |
Comparison of the effects of fenamates on Ca-activated chloride and potassium currents in rabbit portal vein smooth muscle cells.
Topics: Animals; Calcium; Chloride Channels; Evoked Potentials; Female; Flufenamic Acid; In Vitro Techniques; Mefenamic Acid; Membrane Potentials; Molecular Structure; Muscle, Smooth, Vascular; Niflumic Acid; Portal Vein; Potassium Channels; Rabbits | 1995 |
The action of flufenamic acid and other nonsteroidal anti-inflammatories on sulfate transport in the isolated perfused rat liver.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Biological Transport; Dose-Response Relationship, Drug; Flufenamic Acid; In Vitro Techniques; Liver; Male; Mefenamic Acid; Naproxen; Niflumic Acid; Perfusion; Piroxicam; Rats; Rats, Wistar; Sulfates; Sulfonamides; Sulfur Radioisotopes; Time Factors | 1999 |
Capillary isotachophoretic determination of flufenamic, mefenamic, niflumic and tolfenamic acid in pharmaceuticals.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Calibration; Dosage Forms; Electrophoresis; Flufenamic Acid; Mefenamic Acid; Niflumic Acid; ortho-Aminobenzoates; Pharmaceutical Preparations; Reproducibility of Results | 2000 |
Selective inhibition of Cl(-) conductance in toad skin by blockers of Cl(-) channels and transporters.
Topics: Angiogenesis Inhibitors; Animals; Anion Transport Proteins; Anti-Inflammatory Agents, Non-Steroidal; Bufonidae; Bumetanide; Calcium Channel Blockers; Carrier Proteins; Chloride Channels; Chlorides; Cyclooxygenase Inhibitors; Diuretics; Dose-Response Relationship, Drug; Electric Conductivity; Eosine Yellowish-(YS); Flufenamic Acid; Fluorescent Dyes; Furosemide; Mefenamic Acid; Membrane Potentials; Niflumic Acid; Nitrobenzoates; ortho-Aminobenzoates; Patch-Clamp Techniques; Skin | 2001 |
Glucuronidation of fenamates: kinetic studies using human kidney cortical microsomes and recombinant UDP-glucuronosyltransferase (UGT) 1A9 and 2B7.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Flufenamic Acid; Glucuronides; Glucuronosyltransferase; Humans; Kidney; Kidney Cortex; Kinetics; Mefenamic Acid; Microsomes; Niflumic Acid; ortho-Aminobenzoates; Recombinant Proteins; UDP-Glucuronosyltransferase 1A9 | 2007 |
Modulation of glutamate and glycine transporters by niflumic, flufenamic and mefenamic acids.
Topics: Amino Acid Transport System X-AG; Animals; Dose-Response Relationship, Drug; Female; Flufenamic Acid; Glycine Plasma Membrane Transport Proteins; Mefenamic Acid; Membrane Potentials; Niflumic Acid; Xenopus laevis | 2009 |
Effect of 2-hydroxypropyl-β-cyclodextrin on solubility of sparingly soluble drug derivatives of anthranilic acid.
Topics: 2-Hydroxypropyl-beta-cyclodextrin; beta-Cyclodextrins; Flufenamic Acid; Mefenamic Acid; Niflumic Acid; ortho-Aminobenzoates; Solubility; Spectrophotometry, Ultraviolet; Temperature; Thermodynamics | 2011 |
Cobalt(II) complexes with non-steroidal anti-inflammatory drugs and α-diimines.
Topics: 2,2'-Dipyridyl; Aminopyridines; Anti-Inflammatory Agents, Non-Steroidal; Binding Sites; Biphenyl Compounds; Cations, Divalent; Cobalt; Coordination Complexes; Crystallography, X-Ray; Diflunisal; DNA; Flufenamic Acid; Free Radical Scavengers; Intercalating Agents; Kinetics; Mefenamic Acid; Methanol; Models, Molecular; Niflumic Acid; Phenanthrolines; Picrates; Serum Albumin | 2016 |